"
Team:RAMNOTIREN CALGARY/References
From 2014hs.igem.org
(Difference between revisions)
| (6 intermediate revisions not shown) | |||
| Line 260: | Line 260: | ||
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY" id="homelink">Home</a></li> | <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY" id="homelink">Home</a></li> | ||
| - | <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/ | + | <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Members" id="teamlink">Team</a> |
<ul> | <ul> | ||
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Members">Members</a></li> | <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Members">Members</a></li> | ||
| - | <li><a href="https://igem.org/Team.cgi" target="_blank">Official Profile</a></li> | + | <li><a href="https://igem.org/Team.cgi?id=1295" target="_blank">Official Profile</a></li> |
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/AboutCMHS">About CMHS</a></li> | <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/AboutCMHS">About CMHS</a></li> | ||
</ul> | </ul> | ||
</li> | </li> | ||
| - | + | <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project/Content" id="projectlink">Project </a> | |
<ul> | <ul> | ||
| - | <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project/Content"> | + | <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project/Content">Overview</a></li> |
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/HumanPractices">Human Practices</a></li> | <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/HumanPractices">Human Practices</a></li> | ||
| + | <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project/Safety">Safety</a></li> | ||
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/References">References</a></li> | <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/References">References</a></li> | ||
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Attributions">Attributions</a></li> | <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Attributions">Attributions</a></li> | ||
| Line 281: | Line 282: | ||
<li><a class="drop" href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Notebook" id="notebooklink">Notebook</a></li> | <li><a class="drop" href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Notebook" id="notebooklink">Notebook</a></li> | ||
| - | <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/ | + | <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Protocols" id="protocollink">Protocols</a></li> |
<li><a href="https://2014hs.igem.org" target="_blank">iGEM</a></li> | <li><a href="https://2014hs.igem.org" target="_blank">iGEM</a></li> | ||
| Line 287: | Line 288: | ||
</div> | </div> | ||
</header> | </header> | ||
| + | |||
| + | <div id="reference"> | ||
| + | <h3>References</h3><br> | ||
| + | |||
| + | A New Strategy in the War on Cancer. (2009, October 1). . Retrieved , from http://www.ted.com/talks/david_agus_a_new_strategy_in_the_war_on_cancer.html<br> | ||
| + | Targeted Cancer Therepy. (n.d.). . Retrieved , from | ||
| + | http://www.cancer.org/acs/groups/cid/documents/webcontent/003024-pdf.pdf<br> | ||
| + | http://new.ted.com/playlists/63/a_cure_for_cancer<br> | ||
| + | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC205287/ <br> | ||
| + | http://biotech.szbk.u-szeged.hu/RG_Jegyzet/pBADg3_man.pdf <br> | ||
| + | http://www.wisegeek.com/what-is-endostatin.htm <br> | ||
| + | |||
| + | <h3>Papers:</h3> | ||
| + | Hooke, A., Oeschger, M. P., Zeligs, B., & Bellanti, J. Ideal Target Organism for Quantitative Bactericidal Assays. Infection and Immunity.<br> | ||
| + | Anti-angiogenesis mediated by angiostatin K1–3, K1–4 and K1–4.5; Anti Angiogenesis mediated by angiostatin.<br> Endothelium and Vascular Development<br> | ||
| + | Nussenbaum, F., & Herman, I. N. Tumor Angiogenesis . Insights and Innovations, 2010.<br> | ||
| + | Antiangiogenic peptides and proteins; https://d2l.cbe.ab.ca/d2l/le/content/306178/viewContent/3812058/View | ||
| + | Recombinant Human Angiostatin by Twice-Daily Subcutaneous Injection in Advanced Cancer<br> | ||
| + | |||
| + | |||
</body> | </body> | ||
</html> | </html> | ||
Latest revision as of 03:59, 21 June 2014
References
A New Strategy in the War on Cancer. (2009, October 1). . Retrieved , from http://www.ted.com/talks/david_agus_a_new_strategy_in_the_war_on_cancer.html
Targeted Cancer Therepy. (n.d.). . Retrieved , from http://www.cancer.org/acs/groups/cid/documents/webcontent/003024-pdf.pdf
http://new.ted.com/playlists/63/a_cure_for_cancer
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC205287/
http://biotech.szbk.u-szeged.hu/RG_Jegyzet/pBADg3_man.pdf
http://www.wisegeek.com/what-is-endostatin.htm
Papers:
Hooke, A., Oeschger, M. P., Zeligs, B., & Bellanti, J. Ideal Target Organism for Quantitative Bactericidal Assays. Infection and Immunity.Anti-angiogenesis mediated by angiostatin K1–3, K1–4 and K1–4.5; Anti Angiogenesis mediated by angiostatin.
Endothelium and Vascular Development
Nussenbaum, F., & Herman, I. N. Tumor Angiogenesis . Insights and Innovations, 2010.
Antiangiogenic peptides and proteins; https://d2l.cbe.ab.ca/d2l/le/content/306178/viewContent/3812058/View Recombinant Human Angiostatin by Twice-Daily Subcutaneous Injection in Advanced Cancer
